Introduction
============

Cigarette smoking is the largest preventable cause of morbidity and mortality in the world. Despite best available treatments, smoking cessation remains an elusive goal for most smokers and relapse is normal. Cigarette smoking behavior is influenced, in part, by genetic factors \[[@B1]\]. Incorporating smoking-related genetic risk information into clinical practice has the potential to increase smoking cessation rates and improve public health. Here, we discuss the clinical implications of emerging findings from genome-wide association studies (GWASs) for smoking behavior and pharmacogenetic trials of cessation treatments. We suggest that research from multiple disciplines should be conducted in parallel to bring us closer to the goal of delivering personalized cessation treatment for smokers.

GWASs of smoking behavior
=========================

Since 2007, several GWASs among individuals of European ancestry have been conducted for different smoking phenotypes, including smoking initiation (ever versus never smokers), age of smoking initiation, number of cigarettes smoked per day (CPD), nicotine dependence (based on the Fagerström test for nicotine dependence score), smoking cessation (former versus current smokers), pack-years and duration of smoking (see Supplementary Table 1 in \[[@B2]\]). Most recently, meta-analyses were conducted among 143,023 individuals of European ancestry \[[@B2]-[@B4]\]. Remarkably, whereas previous GWASs for other complex traits with far smaller sample sizes had discovered multiple novel variants, only one locus on chromosome 15, which harbors the cluster of nicotinic acetylcholine receptor genes *CHRNA3-CHRNA5-CHRNB4*, has been robustly associated with CPD across multiple GWAS of smoking \[[@B2]-[@B7]\]. The single nucleotide polymorphism (SNP) rs1051730 was identified as being most strongly associated with CPD; each copy of the variant allele (allele frequency = 0.35) was estimated to increase smoking by approximately one cigarette per day and accounted for only 0.5% of the variance in CPD \[[@B2]\].

The statistical power bestowed by the tremendous sample sizes of the GWAS meta-analyses for smoking effectively exclude the potential of identifying large effects (\>1.5) for common allele frequencies represented on current GWAS chips. However, additional loci for smoking behavior can be identified as a result of the improved genomic coverage of newer GWAS chips and by analyses of the 1000 Genomes project, which will enable an extension of systematic GWAS methods to SNPs with 1 to 5% allele frequencies \[[@B8]\]. In addition, future GWASs that refine phenotypic characterization of cessation by incorporating longitudinal data on prospective quit attempts and relapses among smokers may reveal loci associated with quitting smoking. Algorithms that incorporate multiple risk variants and their interactions also may yield stronger associations for different smoking behaviors.

Clinical validity of GWAS findings for smoking
==============================================

Because of their low penetrance and inability to explain more than a small fraction of observed heritability, individual SNPs identified in GWASs are generally regarded as lacking sufficient sensitivity, specificity and predictive value to serve as clinical markers of heightened risk of nicotine dependence and persistent smoking in the general population \[[@B9]\]. To translate into a clinically valid marker, a risk factor has to be very strongly associated with a trait. Ware \[[@B10]\] demonstrated that even a marker with an odds ratio as high as 3.58 will not perform well as a predictive test for individual patients. Although we evaluated CPD as a quantitative variable in the GWAS meta-analysis \[[@B2]\], the observed effect size was not sufficiently large. Furthermore, whether the SNPs identified in GWASs for CPD are relevant for cessation is unclear. Although there seems to be partial overlap between some genomic regions associated with CPD and cessation \[[@B11]\], SNPs in *CHRNA3-CHRNA5-CHRNB4*have not been associated with smoking cessation in previous GWASs \[[@B2]-[@B4]\].

The effect sizes of SNPs on smoking behaviors may be larger in the context of gene-environment interactions in therapeutic clinical trials (pharmacogenetics) \[[@B12]\]. Pharmacogenetic studies of smoking cessation therapies may help identify subgroups of smokers who respond more favorably to specific treatments and help determine their optimal dose and duration of treatment. So far, pharmacogenetic trials of smoking cessation suggest that genetic variation in nicotine metabolizing enzymes and dopamine and opioid pathways may have a role in the efficacy of nicotine replacement therapy (NRT), whereas variation in the dopamine pathway may be relevant for response to the smoking cessation drug bupropion \[[@B13]\].

GWASs in pharmacogenetic studies
================================

In pharmacogenetic studies, GWASs may have even greater potential to identify loci associated with improved cessation and, in particular, rare adverse events \[[@B12],[@B14]\]. Preliminary evidence from the first pharmacogenetic GWAS of smoking cessation \[[@B15]\] suggests that regions associated with successful abstinence on bupropion or NRT are not identical, supporting observations from candidate gene pharmacogenetic studies discussed above \[[@B13]\], but replication is required. Given the rare but serious potential psychiatric side-effects of non-nicotinic pharmacotherapies \[[@B16]\], GWASs of bupropion and other therapies, such as varenicline, are warranted.

Future directions
=================

Clearly, changes in public policy, including indoor air acts, increased taxes on cigarettes and bans on tobacco product advertising, have contributed significantly to a decrease in smoking prevalence in the US \[[@B17]\]. However, given that the prevalence of current smokers seems to be stabilizing, and existing cessation treatments help only a fraction of smokers to quit, new tailored approaches for cessation that involve insights from genetics deserve to be considered.

Although substantial progress has been made in the genetics of smoking in recent years, more research is needed. To maximize the potential for personalized treatment for smokers, translational research from multiple disciplines should be conducted in parallel with ongoing GWASs for smoking behavior and pharmacogenetic studies of smoking cessation. Behavioral research on the uptake, understanding and consequences of genetic risk communication will increase the likelihood that future genetic testing of smoking will result in public health improvements \[[@B18]\] and reduce the likelihood of harm; such harm could include a lowering of the motivation to quit or of the self-efficacy for quitting, both of which could undermine quitting efforts. Research surrounding the ethical, legal and social implications of genetic research on smoking \[[@B19]\] will help us handle the potential discrimination against patients related to inappropriate use of their genetic information, given the known co-morbidity between nicotine dependence and other substance abuse conditions and psychiatric disorders, the possibility of pleiotropic associations and the differential prevalence of risk-conferring genotypes among different ancestries. Cost-benefit analyses of genetically tailored treatment for smoking will contribute to the feasibility of these approaches. Finally, development of genetic testing guidelines for and training of health care providers is needed to standardize care and increase their confidence in interpreting and conveying results to their patients \[[@B20]\].

The coordinated effort of multidisciplinary research teams that address these complex issues will help inform the circumstances under which we can translate the genetics of smoking into clinical practice in the hope of reducing the burden of smoking in our society. Until the goal of personalized cessation treatment is realized, all smokers should be encouraged to quit, regardless of genotype.
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